



an Open Access Journal by MDPI

## Marine Compounds and Inflammation II

Guest Editors:

**Prof. Dr. Agostino Casapullo**

Department of Pharmacy,  
University of Salerno, via  
Giovanni Paolo II 132, 84084  
Fisciano, Italy

**Prof. Dr. Virginia Motilva**

Department of Pharmacology,  
School of Pharmacy, University of  
Seville, Seville, Spain

Deadline for manuscript  
submissions:

**closed (15 December 2020)**


### Message from the Guest Editors

Marine metabolites own a unique chemical diversity, containing structural requirements that allow binding to specific targets, and cover a wide range of biological properties that are closely related to their pharmacological potential and therapeutic success in the most diverse diseases. The drug discovery process is moving toward a rationalization in which chemistry and pharmacology converge towards targeted approaches, focused on specific diseases and molecular targets. Inflammation is a defensive response of an organism in which harmful factors, such as pathogens, heat, and cancer cells produce tissue damage. It involves a multitude of cell types, chemical mediators, and interactions. An enormous demand exists for new and potent anti-inflammatory drugs because inflammation underlies a multitude of human diseases, including atherosclerosis, inflammatory bowel diseases, diabetes, rheumatoid arthritis, Alzheimer's disease, and, in particular, the start and progression of cancer. As Guest Editors of this Special Issue of Marine Drugs, we invite you to report your findings in the field of marine anti-inflammatory compounds.



[mdpi.com/si/32201](https://mdpi.com/si/32201)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Bill J. Baker

Department of Chemistry,  
University of South Florida, 4202  
E. Fowler Ave., CHE 205, Tampa,  
FL 33620-5250, USA

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

## Contact Us

---

*Marine Drugs* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/marinedrugs](http://mdpi.com/journal/marinedrugs)  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)  
[X@Marine\\_Drugs](#)